Brief: Oragenics Enters Into Agreement With Lantern Bioworks For Replacement-Therapy Assets
29/09/2023 21:31
Sept 29 (Reuters) - Oragenics Inc OGEN.A :
* ORAGENICS ENTERS INTO AGREEMENT WITH LANTERN BIOWORKS FOR
REPLACEMENT-THERAPY ASSETS
Source text for Eikon: ID:nBw1075t9a
Further company coverage: OGEN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing